ASTH Quote, Financials, Valuation and Earnings

Biote has a net margin of -1.05% compared to Astrana Health's net margin of 7.43%. Astrana Health's return on equity of 9.13% beat Biote's return on equity of --.

Astrana Health has a consensus price target of $50.5000, signalling upside risk potential of 51.04%. On the other hand Biote has an analysts' consensus of $7.47 which suggests that it could grow by 99.64%. Given that Biote has higher upside potential than Astrana Health, analysts believe Biote is more attractive than Astrana Health.

Astrana Health has a beta of 0.998, which suggesting that the stock is 0.209% less volatile than S&P 500. In comparison Biote has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Astrana Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biote offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astrana Health pays 9.35% of its earnings as a dividend. Biote pays out 150.27% of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Biote's is not.

Astrana Health quarterly revenues are $665.2M, which are larger than Biote quarterly revenues of $49.8M. Astrana Health's net income of -$7M is lower than Biote's net income of $3.7M. Notably, Astrana Health's price-to-earnings ratio is 37.57x while Biote's PE ratio is 20.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astrana Health is 0.79x versus 0.65x for Biote. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of -1.05% compared to Astrana Health's net margin of 3.55%. Astrana Health's return on equity of 9.13% beat Cryo-Cell International's return on equity of --.

Astrana Health has a consensus price target of $50.5000, signalling upside risk potential of 51.04%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 66.83%. Given that Cryo-Cell International has higher upside potential than Astrana Health, analysts believe Cryo-Cell International is more attractive than Astrana Health.

Astrana Health has a beta of 0.998, which suggesting that the stock is 0.209% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.595%.

Astrana Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 9.81% to investors and pays a quarterly dividend of $0.25 per share. Astrana Health pays 9.35% of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Cryo-Cell International's is not.

Astrana Health quarterly revenues are $665.2M, which are larger than Cryo-Cell International quarterly revenues of $8M. Astrana Health's net income of -$7M is lower than Cryo-Cell International's net income of $282.9K. Notably, Astrana Health's price-to-earnings ratio is 37.57x while Cryo-Cell International's PE ratio is 509.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astrana Health is 0.79x versus 1.30x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

Omnicell has a net margin of -1.05% compared to Astrana Health's net margin of -2.6%. Astrana Health's return on equity of 9.13% beat Omnicell's return on equity of 1.73%.

Astrana Health has a consensus price target of $50.5000, signalling upside risk potential of 51.04%. On the other hand Omnicell has an analysts' consensus of $42.17 which suggests that it could grow by 66.08%. Given that Omnicell has higher upside potential than Astrana Health, analysts believe Omnicell is more attractive than Astrana Health.

Astrana Health has a beta of 0.998, which suggesting that the stock is 0.209% less volatile than S&P 500. In comparison Omnicell has a beta of 0.776, suggesting its less volatile than the S&P 500 by 22.397%.

Astrana Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omnicell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astrana Health pays 9.35% of its earnings as a dividend. Omnicell pays out -- of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Astrana Health quarterly revenues are $665.2M, which are larger than Omnicell quarterly revenues of $269.7M. Astrana Health's net income of -$7M is higher than Omnicell's net income of -$7M. Notably, Astrana Health's price-to-earnings ratio is 37.57x while Omnicell's PE ratio is 55.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astrana Health is 0.79x versus 1.04x for Omnicell. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners has a net margin of -1.05% compared to Astrana Health's net margin of -12.84%. Astrana Health's return on equity of 9.13% beat P3 Health Partners's return on equity of -26.35%.

Astrana Health has a consensus price target of $50.5000, signalling upside risk potential of 51.04%. On the other hand P3 Health Partners has an analysts' consensus of $16.25 which suggests that it could grow by 90.06%. Given that P3 Health Partners has higher upside potential than Astrana Health, analysts believe P3 Health Partners is more attractive than Astrana Health.

Astrana Health has a beta of 0.998, which suggesting that the stock is 0.209% less volatile than S&P 500. In comparison P3 Health Partners has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Astrana Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astrana Health pays 9.35% of its earnings as a dividend. P3 Health Partners pays out -- of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Astrana Health quarterly revenues are $665.2M, which are larger than P3 Health Partners quarterly revenues of $362.1M. Astrana Health's net income of -$7M is higher than P3 Health Partners's net income of -$46.5M. Notably, Astrana Health's price-to-earnings ratio is 37.57x while P3 Health Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astrana Health is 0.79x versus 0.02x for P3 Health Partners. Usually stocks with elevated PS ratios are considered overvalued.